Bog Bilberry recognized as new dietary ingredient for US market

By Adi Menayang contact

- Last updated on GMT

Photo: David Gaya/Wikimedia Commons
Photo: David Gaya/Wikimedia Commons
The Food and Drug Administration (FDA) now recognizes bog bilberry, or Vaccinium uliginosum, as a new dietary ingredient for the US market, South Korean manufacturer Dong-A Pharmaceutical announced.

A new dietary ingredient (NDI) notification was originally submitted by Dong-A Pharmaceutical​ back in December 2015, with the help of a regulatory management consulting firm Ingredient Identity​.

"Achieving an NDI status from the FDA validates the safety of the ingredient and will help to greatly expand our business in the United States, specifically in the Dietary Supplement market,”​ said Yong Sam Kwon, Research Fellow in the Consumer Product Research division of Dong-A Pharmaceutical.

Studies on the extract

The flowering plant, which grows in cool temperate regions of the Northern Hemisphere, has been studied for it antioxidant capabilities, specifically eye and skin health. A search on PubMed revealed that there have been 14 studies in the past 10 years on bog bilberry​, seven of which were human studies.

One 2016 study​ by researchers at Dongguk University found that oral intake of bog bilberry extract for 1000 mg/day for four weeks alleviated eye strain symptoms caused by tablet computer watching. Another study from 2009​ found that, in vitro​, anthocyanins of bog bilberry extract supported UV-induced skin aging signs.

Currently, up to 500mg/day is the suggested daily usage of bog bilberry deemed safe. “The bog bilberry custom extract is far superior to other conventional bilberry ingredients in the marketplace due to its very unique anthocyanin profile and total polyphenol content, which have been studied extensively in Korea and abroad,”​ according to the company.

“This success serves as a blue print for many other new ingredients currently in development,”​ Kwon added. “This NDI status is a great accomplishment given high number of notifications that receive objection letters following the rigorous review process by the FDA."

Related news

Show more

Related products

show more

omnilean

A Modern Look At Managing Blood Sugar

OmniActive Health Technologies | 14-Nov-2017 | Technical / White Paper

Sugar is ubiquitous and addictive. Over the past 30 years, sugar consumption has steadily increased, contributing to the growing epidemic of elevated blood...

SelenoForce®: Micro-Nutrient with Macro-Potential

SelenoForce®: Micro-Nutrient with Macro-Potential

Sabinsa Corporation | 16-Oct-2017 | Data Sheet

A safe and bioavailable source of supplemental selenium, this selenium-enriched garlic product is manufactured by a patented soil-less culture technique,...

Related suppliers

comments

Post your comment

We will not publish your email address on the website

These comments have not been moderated. You are encouraged to participate with comments that are relevant to our news stories. You should not post comments that are abusive, threatening, defamatory, misleading or invasive of privacy. For the full terms and conditions for commenting see clause 7 of our Terms and Conditions ‘Participating in Online Communities’. These terms may be updated from time to time, so please read them before posting a comment. Any comment that violates these terms may be removed in its entirety as we do not edit comments. If you wish to complain about a comment please use the "REPORT ABUSE" button or contact the editors.

Follow us

Products

View more

Webinars